Groups representing health centers, HIV/AIDS clinics, and hospitals asked federal appeals courts in Philadelphia and Washington, D.C., this week to hold that drug manufacturers must give covered entities 340B discounts on drugs when entities use contract pharmacies to
…
One-third (33%) of community health center (CHC) senior executives whose organizations do not currently have an on-site pharmacy plan to open one in the next three years, a new survey shows.
Legislation in Connecticut that would have kept drug manufacturers from imposing “any preconditions, limitations, delays or other barriers” to 340B drug purchases “that are not required” by the 340B statute, died when this year’s legislative session ended on
…
The Colorado General Assembly has voted to stop health insurers, pharmacy benefit managers (PBMs), and other third-party payers from discriminating against 340B covered entities and their contract pharmacies.
The U.S. uninsured rate fell slightly in 2021 to 9.2% (about 30 million people), down from 9.7% (about 31.6 million people) in 2020, the National Center for Health Statistics (NCHS) reports.
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies violate federal law and ultimately diminish states’ public health efforts, 25 states told two federal appeals courts yesterday.
An American Action Forum (AAF) data analysis that connects increases in consumer drug spending with the introduction of 340B drug discount and Medicaid drug rebate program policies “is spurious at best,” says an expert on prescription drug costs
…
The U.S. Health Resources and Services Administration (HRSA) yesterday announced 340B program enrollment flexibilities in New Mexico due to the declaration of a public health emergency in the state.
Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.
